

Patient: DOB: Age: 57	Sex: F	Client:	ARUP Test Code: 2009288
Patient Identifiers:	Jea. F		Collection Date:
Visit Number (FIN):		Physician:	Received in lab: 11/26/2023 Completion Date: 12/01/2023

Interpretive Summary

See Note

Interpretive Consultation

NO DRUGS PROVIDED

Please call ARUP Laboratories Client Services at 800-522-2787 for Medical Director interpretation if applicable. Alternatively, please consider the TARGETED DRUG PROF, MASS SPEC/EMIT, UR (2007479) which does not require medication information or provide compliance interpretation.

Interpretation depends on accuracy and completeness of patient medication information submitted by client.

Patient Results - Current *				
Collection Date				
Creatinine, Urine	66.3			
Methadone Screen, U	Negative			
Tramadol Screen, U	Negative			
Cocaine Screen, U	Negative			
Barbiturates Screen, U	Negative			
Ethyl Glucuronide Screen, U	Negative			
THC (Cannabinoids) Screen, U	Negative			
Phencyclidine Screen, U	Negative			
Carisoprodol Screen, U	Negative			
Hydrocodone, U	Present			
Norhydrocodone, U	Present			
Hydromorphone, U	Present			
Amphetamine, U	Present			
ARUP Accession	23-328-112327			



ARUP LABORATORIES | 800-522-2787 | arupiab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



Chart continues on following page(s) ARUP Enhanced Reporting | December 01, 2023 | page 1 of 5

Patient: | Date of Birth: | Sex: F | Physician: Patient Identifiers: | Visit Number (FIN):

* For details, see report on following page.

NOTE: Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult the patient's prior charts.

Interpretive Comments

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not fit clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available at an additional fee within two weeks of specimen collection.

For medical purposes only; not valid for forensic use.

For further information, consult aruplab.com/pain.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 23-328-112327

Chart continues on following page(s) ARUP Enhanced Reporting | December 01, 2023 | page 2 of 5

	Number (FIN):	<u> </u>	
Drug Analyte	Result	Cutoff	Notes
OPIOIDS, IMMUNOASSAY			
Methadone	Negative		
Tramadol	Negative		
COCAINE, IMMUNOASSAY			
Benzoylecgonine	Negative		cocaine metabolite
BARBITURATES, IMMUNOASSAY			
Barbiturates	Negative		detects amobarbital, butalbital, pentobarbital, phenobarbital, secobarbital, and others
OTHERS (IMMUNOASSAY OR SPECTROPHOTOMETRY)			
Ethyl glucuronide	Negative		ethanol metabolite
Marijuana metabolite	Negative		9-carboxy-tetrahydrocannabinol; does not distinguish between prescribed and illicit forms
PCP	Negative		phencyclidine
Carisoprodol	Negative	100 ng/mL	detects carisoprodol and meprobamate
OPIATES, MASS SPEC			
Codeine	Not Detected		
Morphine	Not Detected		also a metabolite of Codeine; may reflect poppy seed ingestion
6-acetylmorphine	Not Detected		heroin metabolite; morphine is expected
OXYCODONE-LIKE, MASS SPEC			
Oxycodone	Not Detected		
Noroxycodone	Not Detected		oxycodone metabolite
Oxymorphone	Not Detected		eg, Opana; also a metabolite of oxycodone
Noroxymorphone	Not Detected		oxymorphone metabolite; naloxone metabolite (i.e., nornaloxone)
Hydrocodone	Present		also a minor metabolite of Codeine; possible impurity of oxycodone
Norhydrocodone	Present		hydrocodone metabolite
Hydromorphone	Present		eg, Dilaudid; also a metabolite of hydrocodone, and a minor metabolite of morphine
OPIOIDS, MASS SPEC			
Buprenorphine	Not Detected		eg Suboxone, Subutex
Norbuprenorphine	Not Detected		buprenorphine metabolite
Fentanyl	Not Detected		
Norfentanyl	Not Detected		fentanyl metabolite
Meperidine metabolite	Not Detected		normeperidine



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 23-328-112327

Chart continues on following page(s) ARUP Enhanced Reporting | December 01, 2023 | page 3 of 5

Drug Analyte	Result	Cutoff	Notes
Tapentadol	Not Detected	outon	Notes
Tapentadol-o-sulfate	Not Detected		tapentadol metabolite
OPIOIDS ANTAGONIST, MASS SPEC			
Naloxone	Not Detected		eg, Narcan; also coformulated in Suboxone
GABA ANALOGUES, MASS SPEC			
Gabapentin	Not Detected		
Pregabalin	Not Detected		eg, Lyrica
AMPHETAMINE-LIKE, MASS SPEC			
Amphetamine	Present		eg, Vyvanse; also a metabolite of methamphetamine
Methamphetamine	Not Detected		d- and I- isomers are not distinguished by this test; may reflect Vicks inhaler, Desoxyn, Selegiline, or illicit source
MDMA - Ecstasy	Not Detected		
MDA	Not Detected		also a metabolite of MDMA and MDEA
MDEA - Eve	Not Detected		
Phentermine	Not Detected		
Methylphenidate	Not Detected		eg, Ritalin, Dexmethylphenidate, Focalin, Concerta
BENZODIAZEPINE-LIKE, MASS SPEC			
Alprazolam	Not Detected		eg, Xanax
Alpha-hydroxyalprazolam	Not Detected		alprazolam metabolite
Clonazepam	Not Detected		eg, Klonopin
7-aminoclonazepam	Not Detected		clonazepam metabolite
Diazepam	Not Detected		eg, Valium
Nordiazepam	Not Detected		metabolite of chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam, halazepam (Alapryl), prazepam (Centrax) and others
Oxazepam	Not Detected		eg, Serax; also metabolite of nordiazepam and temazepam
Temazepam	Not Detected		eg, Restoril; also a metabolite of diazepam
Lorazepam	Not Detected		eg, Ativan
Midazolam	Not Detected		eg, Versed
Alpha-OH-Midazolam	Not Detected		midazolam metabolite
Zolpidem	Not Detected		eg, Ambien
Zolpidem Metabolite	Not Detected		zolpidem 4-phenyl carboxylic acid
		Reference interval	
Creatinine value (mg/dL)	66.3	20.0 - 400.0 mg/dL	

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director

四

Ð

2

Patient: ARUP Accession: 23-328-112327

Chart continues on following page(s) ARUP Enhanced Reporting | December 01, 2023 | page 4 of 5

Patient:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:
Image: Section of Birth:

Patient Identifiers:
Image: Section of Birth:
Image: Section of Birth:
Image: Section o

Additional Information

METHODOLOGIES USED

Qualitative Enzyme Immunoassay Qualitative Liquid Chromatography-Tandem Mass Spectrometry Quantitative Spectrophotometry

ABBREVIATIONS

MASS SPEC - Mass Spectrometry MDA - 3,4-methylenedioxyamphetamine MDEA - 3,4-methylenedioxy-N-ethylamphetamine MDMA - 3,4-methylenedioxy-N-methylamphetamine



ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: ARUP Accession: 23-328-112327